Three cases of rabies have been confirmed in raccoons and a bat that were caught during the past two weeks in the Town of Lockport, the Niagara County Department of Health reported. The first ...
Merck (NYSE:MRK) said a pivotal Phase 3 study for its drug Winrevair in the treatment of pulmonary arterial hypertension, or PAH, has met its primary endpoint. Topline results from the study ...
2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR ...
(RTTNews) - Merck & Co., Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Monday positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk ...
Eight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 billion Acceleron acquisition. In the phase 3 ZENITH study, Merck’s ...
RAHWAY, N.J. - Merck (NS:PROR) & Co., Inc., a leading pharmaceutical company, announced significant progress in its Phase 3 ZENITH study for WINREVAIR (sotatercept-csrk), a treatment for pulmonary ...
Second positive phase 3 trial adds to growing body of evidence for WINREVAIR, an activin signaling inhibitor therapy that targets an underlying cause of PAH Merck (NYSE: MRK), known as MSD outside of ...
Second positive phase 3 trial adds to growing body of evidence for WINREVAIR, an activin signaling inhibitor therapy that targets an underlying cause of PAH Merck (NYSE: MRK), known as MSD outside ...
FRESNO COUNTY, Calif. (KFSN) -- Health officials are investigating a rabies exposure in a Fresno County resident. The Department of Public Health tells Action News a Fresno resident is suspected ...
The news came in a brief statement, which followed a surprise success for anacetrapib in the large multi-billion dollar phase 3 REVEAL trial earlier this year. Merck & Co was the last big pharma ...
Merck (MRK) announced positive topline results from the Phase 3 ZENITH study evaluating Winrevair in adults with pulmonary arterial hypertension functional class III or IV at high risk of mortality.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback